Bristol myers squibb completes acquisition of puretech's founded entity karuna therapeutics for $14 billion

Boston--(business wire)--puretech health plc (nasdaq: prtc, lse: prtc) (“puretech” or the “company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its founded entity, karuna therapeutics, inc. ("karuna”), by bristol myers squibb (nyse: bmy) (“bms”), which has acquired all outstanding common stock of karuna for $330.00 per share, for a total equity value of approximately $14 billion. "this acquisition recognizes the enormous potential of karxt to help mi.
PRTC Ratings Summary
PRTC Quant Ranking